T.J. Moretto et al.  Table I. Baseline characteristics of patients with type 2 diabetes randomly assigned to receive 24-week treat-  ment with exenatide or placebo. Values are mean (SD) unless otherwise specified.  Characteristic  Age, y  Mean (SD)  Range  Sex, %  Male  Female  Race, %  White  Asian  Hispanic  Black  Duration of diabetes, y  H bAle, %  FSG, mg/dL  Weight, kg  BMI, kg/m 2  SBP, mm Hg  DBP, mm Hg Exenatide 5 IJg Exenatide 10 IJg Placebo  (n = 77) (n = 78) (n = 77)  54 (10) 55 (10) 53 (9)  28-72 33-77 26-73  52 62 55  48 38 45  2  7.9  166  85  32  129 65 72 66  29 23 27  6 1 3  0 4 4  (3) 2 (3) 1 (2)  (1.0) 7.8 (1.0) 7.8 (0.9)  (49) 154 (40) 160 (46)  (15) 86 (16) 86 (16)  (5) 31 (5) 32 (5)  (11) 130 (12) 129 (12)  78 (7) 78 (8) 79 (8)  HbAlc = glycosylated hemoglobin; FSG = fasting serum glucose; BMI = body mass index; SBP = systolic blood pressure;  DBP = diastolic blood pressure.  day (P = 0.011) and in the evening (P = 0.005). At end